Serum tight-junction proteins predict hemorrhagic transformation in ischemic stroke patients

Neurology

Volumn 79, Issue 16, 2012, Pages 1677-1685

  Kazmierski, Radoslaw ^a   Michalak, Slawomir ^a,b   Wencel Warot, Agnieszka ^a   Nowinski, Wieslaw L ^c  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b POLISH ACADEMY OF SCIENCES   (Poland)

^c AGENCY FOR SCIENCE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CLAUDIN 5; FIBRINOLYTIC AGENT; GELATINASE B; MEMBRANE PROTEIN; NEURON SPECIFIC ENOLASE; OCCLUDIN; PROTEIN S100B; PROTEIN ZO1; TIGHT JUNCTION PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

AGED; ARTICLE; BLOOD BRAIN BARRIER; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; COMPUTER ASSISTED TOMOGRAPHY; DISEASE MARKER; EMERGENCY WARD; FEMALE; HEMORRHAGIC TRANSFORMATION; HOSPITAL ADMISSION; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NEUROLOGIC DISEASE; PRIORITY JOURNAL;

EID: 84871209417     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31826e9a83     Document Type: Article

References (40)

1. del Zoppo GJ, Becker KJ, Hallenbeck JM. Inflammation after stroke: is it harmful? Arch Neurol 2001;58:669-672.
2. Larrue V, von Kummer R, Mǔller A, Bluhmki E. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke 2001; 32:438-441.
3. Paciaroni M, Agnelli G, Corea F, et al. Early hemorrhagic transformation of brain infarction: rate, predictive factors, and influence on clinical outcome: results of a prospective multicenter study. Stroke 2008;39:2249-2256.
4. Lee JH, Park KY, Shin JH, et al. Symptomatic hemorrhagic transformation and its predictors in acute ischemic stroke with atrial fibrillation. Eur Neurol 2010;64:193-200.
5. Benarroch EE. Blood-brain barrier: recent developments and clinical correlations. Neurology 2012;78:1268-1276.
6. McCaffrey G, Staatz WD, Quigley CA, et al. Tight junctions contain oligomeric protein assembly critical for maintaining blood-brain barrier integrity in vivo. J Neurochem 2007;103:2540-2555.
7. Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004;363:768-774.
8. Adams HP, del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke. Stroke 2007;38:1655-1711.
9. Wahlgren N, Ahmed N, Davalos A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007;369: 275-282.
10. Zhang WJ, Feng J, Zhou R, et al. Tanshinone II A protects the human blood-brain barrier model from leukocyteassociated hypoxia-reoxygenation injury. Eur J Pharmacol 2010;648:146-152.
11. Argaw AT, Gurfein BT, Zhang Y, Zameer A, John GR. VEGF-mediated disruption of endothelial CLN-5 promotes blood-brain barrier breakdown. Proc Natl Acad Sci USA 2009;106:1977-1982.
12. Fujimura M, Gasche Y, Morita-Fujimura Y, Massengale J, Kawase M, Chan PH. Early appearance of activated matrix metalloproteinase-9 and blood-brain barrier disruption in mice after focal cerebral ischemia and reperfusion. Brain Res 1999;842:92-100.
13. Rosenberg GA, Estrada EY, Dencoff JE. Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. Stroke 1998; 29:2189-2195.
14. Foerch C, Wunderlich MT, Dvorak F, et al. Elevated serum S100B levels indicate a higher risk of hemorrhagic transformation after thrombolytic therapy in acute stroke. Stroke 2007;38:2491-2495.
15. Shi ZS, Loh Y, Walker G, Duckwiler GR; MERCI and Multi MERCI Investigators. Endovascular thrombectomy for acute ischemic stroke in failed intravenous tissue plasminogen activator versus non-intravenous tissue plasminogen activator patients: revascularization and outcomes stratified by the site of arterial occlusions. Stroke 2010;41: 1185-1192.
16. Hacke W, Kaste M, Bluhmki E, et al ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359:1317-1329.
17. Hacke W, Kaste M, Fieschi C, et al. Randomised doubleblind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II): Second European-Australasian Acute Stroke Study Investigators. Lancet 1998;352:1245-1251.
18. van Latum JC, Koudstaal PJ, Venables GS, van Gijn J, Kappelle LJ, Algra A. Predictors of major vascular events in patients with a transient ischemic attack or minor ischemic stroke and with nonrheumatic atrial fibrillation: European Atrial Fibrillation Trial (EAFT) Study Group. Stroke 1995;26:801-806.
19. Adams HP Jr., Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial: TOAST: Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993;24:35-41.
20. Aviv RI, d'Esterre CD, Murphy BD, et al. Hemorrhagic transformation of ischemic stroke: prediction with CT perfusion. Radiology 2009;250:867-877.
21. Thornhill RE, Chen S, Rammo W, Mikulis DJ, Kassner A. Contrast-enhanced MR imaging in acute ischemic stroke: T2 measures of blood-brain barrier permeability and their relationship to T1 estimates and hemorrhagic transformation. AJNR Am J Neuroradiol 2010;31:1015-1022.
22. Colegio OR, Van Itallie C, Rahner C, Anderson JM. Claudin extracellular domains determine paracellular charge selectivity and resistance but not tight junction fibril architecture. Am J Physiol Cell Physiol 2003;284:C1346-C1354.
23. Hirase T, Kawashima S, Wong EY, et al. Regulation of tight junction permeability and occludin phosphorylation by Rhoa-p160ROCK-dependent and-independent mechanisms. J Biol Chem 2001;276:10423-10431.
24. Mark KS, Davies TP. Cerebral microvascular changes in permeability and tight junctions induced by hypoxiareoxygenation. Am J Physiol Heart Circ Physiol 2002;282: H1485-H1494.
25. Yang Y, Estrada EY, Thompson JF, Liu W, Rosenberg GA. Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J Cereb Blood Flow Metab 2007;27:697-709.
26. Furuse M, Hirase T, Itoh M, et al. Occludin: a novel integral membrane protein localizing at tight junctions. J Cell Biol 1993;123:1777-1788.
27. Furuse M, Itoh M, Hirase T, et al. Direct association of occludin with ZO-1 and its possible involvement in the localization of occludin at tight junctions. J Cell Biol 1994;127:1617-1626.
28. Morita K, Sasaki H, Furuse M, Tsukita S. Endothelial claudin: claudin-5/TMVCF constitutes tight junction strands in endothelial cells. J Cell Biol 1999;147:185-194.
29. Balda MS, Anderson JM. Two classes of tight junctions are revealed by ZO-1 isoforms. Am J Physiol 1993;264: C918-C924.
30. Castellanos M, Leira R, Serena J, et al. Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke 2003;34: 40-46.
31. Brown DL, Barsan WG, Lisabeth LD, Gallery ME, Morgenstern LB. Survey of emergency physicians about recombinant tissue plasminogen activator for acute ischemic stroke. Ann Emergency Med 2005;46:56-60.
32. Brea D, Sobrino T, Blanco M, et al. Temporal profile and clinical significance of serum neuron-specific enolase and S100 in ischemic and hemorrhagic stroke. Clin Chem Lab Med 2009;47:1513-1518.
33. Sienkiewicz-Jarosz H, Galecka-Wolska M, Bidzinski A, et al. Predictive value of selected biochemical markers of brain damage for functional outcome in ischaemic stroke patients. Neurol Neurochir Pol 2009;43:126-133.
34. Jiao H, Wang Z, Liu Y, Wang P, Xue Y. Specific role of tight junction proteins claudin-5, occludin, and ZO-1 of the blood-brain barrier in a focal cerebral ischemic insult. J Mol Neurosci 2011;44:130-139.
35. Abumiya T, Yokota C, Kuge Y, Minematsu K. Aggravation of hemorrhagic transformation by early intraarterial infusion of low-dose vascular endothelial growth factor after transient focal cerebral ischemia in rats. Brain Res 2005;1049:95-103.
36. Sobrino T, Arias S, Rodríguez-González R, et al. High serum levels of growth factors are associated with good outcome in intracerebral hemorrhage. J Cereb Blood Flow Metab 2009;29:1968-1974.
37. Lee SC, Lee KY, Kim YJ, Kim SH, Koh SH, Lee YJ. Serum VEGF levels in acute ischaemic strokes are correlated with long-term prognosis. Eur J Neurol 2010;17:45-51.
38. Montaner J, Molina CA, Monasterio J, et al. Matrix Metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 2003;107:598-603.
39. Bang OY, Buck BH, Saver JL, et al. Prediction of hemorrhagic transformation after recanalization therapy using T2*-permeability magnetic resonance imaging. Ann Neurol 2007;62:170-176.
40. Slevin M, Krupinski J, Slowik A, et al. Serial measurement of vascular endothelial growth factor and transforming growth factor-beta1 in serum of patients with acute ischemic stroke. Stroke 2000;31:1863-1870.